Imiquimod treatment of anal Intraepithelial neoplasia in HIV-positive men

被引:84
作者
Wieland, Ulrike
Brockmeyer, Norbert H.
Weissenborn, Soenke J.
Hochdorfer, Bettina
Stuecker, Markus
Swoboda, Jochen
Altmeyer, Peter
Pfister, Herbert
Kreuter, Alexander
机构
[1] Ruhr Univ Bochum, Dept Dermatol & Allergol, D-44791 Bochum, Germany
[2] Univ Cologne, Inst Virol, Cologne, Germany
[3] Inst Cytol, Godesburg, Germany
关键词
D O I
10.1001/archderm.142.11.1438
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To evaluate the treatment of anal intraepithelial neoplasia (AIN) with the local immune response modifier imiquimod in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM). Design: Prospective, nonrandomized, open-label pilot study, with a mean follow-up time of 9 1/2 months. Setting: Dermatology department of a university hospital. Patients: Twenty-eight consecutive HIV-positive MSM with histologically confirmed perianal (n = 23) or intra-anal (n=5) AIN. Intervention: Overnight treatment with self-applied imiquimod cream (perianal AIN) or suppositories (intra-anal AIN) 3 times a week for 16 weeks. Main Outcome Measures: Response to treatment was documented using clinical, cytologic, and histologic criteria. Human papillomavirus (HPV) typing and HPV DNA load determination for the high-risk HPV types 16, 18, 31, and 33 were performed. Results: Seventeen (61%) of all 28 patients included in the study and 17 (77%) of the 22 patients with AIN, who applied imiquimod as instructed, showed clinical and histologic clearance at the end of therapy. Four patients had residual AIN and 1 patient did not improve. Clinical response was accompanied by a sharp decline in HPV DNA loads and by a reduction in the number of HPV types, but long-term HPV clearance was rarely achieved. In the follow-up period, AIN cleared in 3 patients with residual AIN. Fourteen (78%) of 18 imiquimod responders with at least 5 five months of follow-up had a normal cytologic and clinical picture at the end of the follow-up period. Three primary responders developed a recurrence. In 6 noncompliant patients, there was no clinical or morphological improvement and the HPV DNA loads remained high. Conclusions: Imiquimod appears to be a safe and effective treatment option for AIN in HIV-positive MSM. Clinical response is accompanied by a significant decrease in high-risk HPV DNA load. These results should encourage controlled randomized studies of imiquimod treatment of AIN.
引用
收藏
页码:1438 / 1444
页数:7
相关论文
共 37 条
  • [1] Anal intraepithelial neoplasia
    Abbasakoor, F
    Boulos, PB
    [J]. BRITISH JOURNAL OF SURGERY, 2005, 92 (03) : 277 - 290
  • [2] Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%
    Arany, I
    Tyring, SK
    Stanley, MA
    Tomai, MA
    Miller, RL
    Smith, MH
    McDermott, DJ
    Slade, HB
    [J]. ANTIVIRAL RESEARCH, 1999, 43 (01) : 55 - 63
  • [3] Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier
    Arrese, JE
    Paquet, P
    Claessens, N
    Piérard-Franchimont, C
    Piérard, GE
    [J]. JOURNAL OF CUTANEOUS PATHOLOGY, 2001, 28 (03) : 131 - 134
  • [4] Berry J Michael, 2004, Surg Oncol Clin N Am, V13, P355
  • [5] HIV-associated anal cancer - Has highly active antiretroviral therapy reduced the incidence or improved the outcome?
    Bower, M
    Powles, T
    Newsom-Davis, T
    Thirlwell, C
    Stebbing, J
    Mandalia, S
    Nelson, M
    Gazzard, B
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (05) : 1563 - 1565
  • [6] Surgical treatment of high-grade anal squamous intraepithelial lesions - A prospective study
    Chang, GJ
    Berry, JM
    Jay, N
    Palefsky, JM
    Welton, ML
    [J]. DISEASES OF THE COLON & RECTUM, 2002, 45 (04) : 453 - 458
  • [7] Chin-Hong Peter V, 2005, Dermatol Ther, V18, P67, DOI 10.1111/j.1529-8019.2005.05009.x
  • [8] Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency
    Chin-Hong, PV
    Palefsky, JM
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 35 (09) : 1127 - 1134
  • [9] FENGER C, 1986, ACTA PATH MICRO IM A, V94, P63
  • [10] Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome
    Frisch, M
    Biggar, IJ
    Goedert, JJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (18): : 1500 - 1510